This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
VISION Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
RSNA 2022
SUO 2022
Urologists for Social Responsibility 2023
Upcoming
ASCO GU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2022
ASCO GU 2022
Prostate Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
ASCO GU 2022 Kidney Cancer
Viewing 1-20 of 43 articles
ASCO GU 2022: Current Data on Predictive Biomarkers in Renal Cell Carcinoma
ASCO GU 2022: Germline Mutations of Interests in Renal Cell Carcinoma
ASCO GU 2022: Matching Sequencing Reports With Available Therapies in Renal Cell Carcinoma
ASCO GU 2022: Adjuvant and Consolidative Therapy in Oligometastatic Renal Cell Carcinoma
ASCO GU 2022: Updates on Clinical Trials in First-Line Metastatic Renal Cell Carcinoma Plus Novel Pathways and Endpoints
ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma
ASCO GU 2022: SWOG S1931 (PROBE): Phase III Randomized Trial of Immune Checkpoint Inhibitor Combination Regimen with or Without Cytoreductive Nephrectomy in Advanced Renal Cancer
ASCO GU 2022: Prolonging Utilization of Systemic Therapy in Oligoprogressive Metastatic Renal Cell Carcinoma Using Stereotactic Body Radiation Therapy
ASCO GU 2022: Association of Adrenal Metastases With Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma Treated With Nivolumab in the GETUG-AFU-26 NIVOREN Phase II Trial
ASCO GU 2022: Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Sunitinibin the East Asian Subset of Patients With Advanced Renal Cell Carcinoma From the Phase 3 CLEAR Trial
ASCO GU 2022: Tivozanib As First-Line Treatment of Metastatic Renal Cell Carcinoma: A Real-World Outcome Review in North-West of England, UK
ASCO GU 2022: Characterizing IMDC Prognostic Groups in Contemporary First-Line Combination Therapies for mRCC
ASCO GU 2022: CABOSEQ: The Efficacy of Cabozantinib Post Up-Front Immuno-Oncology Combinations in Patients with Advanced Renal Cell Carcinoma: Results from the IMDC
ASCO GU 2022: Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in mRCC: Results From the Canadian Kidney Cancer Information System
ASCO GU 2022: HRQoL in Previously Untreated Patients With Advanced Renal Cell Carcinoma: CheckMate 9ER Updated Results
ASCO GU 2022: Pathologic Outcomes at Cytoreductive Nephrectomy Following Immunotherapy for Patients With Advanced RCC
ASCO GU 2022: First-Line Therapy for Metastatic Renal Cell Carcinoma With Pancreatic Metastases: Results From the IMDC
ASCO GU 2022: Safety and Differential Clinical Activity of Nivolumab plus Ipilimumab in Patients with Non-Clear Cell RCC
ASCO GU 2022: Predictors of Objective Response to First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the IMDC
ASCO GU 2022: Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Treatment-Naïve Patients with Advanced Clear Cell Renal Cell (HCRN GU16-260-Cohort A): Final Report
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free